CVT 313

a potent inhibitor of CDK2 that prevents neointimal proliferation; structure given in first source

Also Known As:

2-(bis-(hydroxyethyl)amino)-6-(4-methoxybenzylamino)-9-isopropyl-purine; CVT-313

Networked: 6 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Purines: 651
      - CVT 313: 6

Experts

1.	Yerlikaya, Azmi: 2 articles (08/2021 - 01/2019)
2.	Dai, Long: 1 article (11/2021)
3.	Hu, Zhong-Dong: 1 article (11/2021)
4.	Li, Xiu-Lian: 1 article (11/2021)
5.	Sun, Yi-Xuan: 1 article (11/2021)
6.	Tao, Yu-Fan: 1 article (11/2021)
7.	Wang, An-Mei: 1 article (11/2021)
8.	Wang, Shao-Ping: 1 article (11/2021)
9.	Wu, Qi: 1 article (11/2021)
10.	Yang, Ai-Lin: 1 article (11/2021)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 01/01/2019 - "In fact, as presented in the current study, Cdc5L phosphorylation inhibitor CVT-313 and DBNL phosphorylation inhibitor OTSSP167 were highly cytotoxic in 4T1 breast cancer cells and their IC50 values were 20.1 and 43 nM, respectively. "
2.	Neoplasms (Cancer) 08/17/2012 - "A CDK2 inhibitor, CVT-313, prevented H(2)O(2)-induced cancer cell proliferation. " 08/01/2020 - "Since this molecule has the potential to be developed as a CDK2 inhibitor for cancer therapy, the potency of CVT-313 to bind and stabilize CDK2 was evaluated, together with its ability to inhibit aberrant cell proliferation. " 08/07/2021 - "Finally, the results showed that while both maternal embryonic leucine zipper kinase (MELK) inhibitor OTSSP167 and Ca2+ chelator BAPTA-AM (also an inhibitor of the expression of antiapoptotic protein GRP78) are promising agents for cancer cells resistant to the proteasome inhibitors, CDK2 inhibitor CVT-313 was found ineffective in both parental and the resistant cells."
3.	Neointima 11/14/1997 - "A brief intraluminal exposure of CVT-313 to a denuded rat carotid artery resulted in more than 80% inhibition of neointima formation. "
4.	Hepatocellular Carcinoma (Hepatoma) 11/15/2021 - "Furthermore, EGFR inhibitor gefitinib or CDK2 inhibitor CVT-313 synergistically enhances anticancer effects of cinobufagin in human hepatoma cells. "
5.	Carcinoma (Carcinomatosis) 08/01/2020 - "CVT-313 inhibited the growth of human lung carcinoma cell line A549 in a dose-dependent manner, with an IC50 of 1.2 µM, which is in line with the reported biochemical potency of 0.5 µM. "

Related Drugs and Biologics

1.	1- (6- (3,5- dichloro- 4- hydroxyphenyl)- 4- ((4- ((dimethylamino)methyl)cyclohexyl)amino)- 1,5- naphthyridin- 3- yl)ethanone
2.	Proteasome Inhibitors
3.	Proteins (Proteins, Gene)
4.	Phosphotransferases (Kinase)
5.	Chelating Agents
6.	Endoplasmic Reticulum Chaperone BiP
7.	Gefitinib (Iressa)
8.	1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester
9.	cinobufagin

Related Therapies and Procedures

1.	Therapeutics